CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has announced the pricing of its underwritten public offering of 2,000,000 shares of common stock at $2.50 per share. The offering is expected to generate gross proceeds of $5,000,000, before expenses. An additional option has been granted to underwriters to purchase up to 190,000 more shares to cover over-allotments. The offering aims to support the ongoing development of CEL-SCI's Multikine product, as well as general corporate purposes and working capital. ThinkEquity is acting as the sole book-running manager. The securities are being offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。